This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes.
Published: 08 January 2020
Number of pages:13
Report code:TL #10167
I think Toujeo is going to be longer-acting, well, it is longer-acting, and I think you just need to be careful because in some patients it might be absolutely right, but in others it might be too long-acting.
It [Toujeo] behaves basically the same as degludec, but you know we had to make a decision because as a unit we try to be sensible about our insulin and our pump choices, I mean, we have a good selection and we get to know them well, and degludec was on the market first, so we decided to use that and it has generally worked well, and I am not sure that swapping across to Toujeo is going to give us much more benefit.
The advantage is that it [Tresiba] is very long-acting, so if people forget their Levemir, it is a great insulin, it is also very stable, is it not? Very stable, so if you inject the same dose every day it is going to give you the same sort of effect, whereas I am not sure you get that with some of the older insulins, that is the advantage. The disadvantage is that it is exactly the same but it is so long-acting that if you were to reduce the dose, say maybe on a day that you wanted to do some exercise you wanted to reduce the dose, it would be two days before it had an effect, so you could not really make meaningful, quick changes.
This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market, the unmet needs in type 1 diabetes, and upcoming therapies in the pipeline. Key marketed and pipeline assets highlighted include Tresiba, Toujeo, Farxiga, and teplizumab.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.